Regina Groves Sells 5,313 Shares of AtriCure (NASDAQ:ATRC) Stock

AtriCure, Inc. (NASDAQ:ATRC) Director Regina Groves sold 5,313 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $54.22, for a total value of $288,070.86. Following the completion of the transaction, the director directly owned 34,546 shares in the company, valued at approximately $1,873,084.12. The trade was a 13.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

AtriCure Price Performance

Shares of NASDAQ ATRC opened at $56.22 on Wednesday. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. The stock has a fifty day moving average price of $43.35 and a 200 day moving average price of $33.91. AtriCure, Inc. has a 1-year low of $25.36 and a 1-year high of $56.78. The company has a market cap of $2.86 billion, a PE ratio of 267.73 and a beta of 1.26.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The firm had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same period last year, the firm posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Sell-side analysts forecast that AtriCure, Inc. will post 0.29 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ATRC. Needham & Company LLC raised their price objective on shares of AtriCure from $45.00 to $64.00 and gave the company a “buy” rating in a research report on Wednesday, September 2nd. UBS Group dropped their target price on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. Zacks Research downgraded AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 24th. Piper Sandler raised their price target on AtriCure from $50.00 to $60.00 and gave the company an “overweight” rating in a report on Thursday, August 27th. Finally, BTIG Research lifted their price target on AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, August 24th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $52.00.

Institutional Trading of AtriCure

A number of institutional investors have recently added to or reduced their stakes in ATRC. Bank of America Corp DE boosted its stake in shares of AtriCure by 13.7% during the 1st quarter. Bank of America Corp DE now owns 768,561 shares of the medical device company’s stock worth $21,927,000 after acquiring an additional 92,830 shares in the last quarter. Man Group plc purchased a new position in AtriCure in the 2nd quarter valued at approximately $684,000. Assenagon Asset Management S.A. acquired a new position in AtriCure during the second quarter worth $1,744,000. Deutsche Bank AG acquired a new position in AtriCure during the second quarter worth $1,670,000. Finally, Rice Hall James & Associates LLC purchased a new stake in AtriCure during the second quarter worth $3,755,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc (NASDAQ: ATRC) is a medical device company focused on the treatment of atrial fibrillation (AF) and related conditions. The company develops, manufactures and sells surgical and minimally invasive technologies designed to restore normal heart rhythm and reduce the risk of stroke associated with AF.

Its product portfolio includes the AtriClip system for excluding the left atrial appendage, the Isolator and Synergy systems for surgical ablation, and the cryoICE system, which uses cryothermal energy in cardiac procedures.